Mangoceuticals Inc. is involved in developing, marketing and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction drug branded `Mango`. Mangoceuticals Inc. is based in DALLAS, TX.
| Revenue (Most Recent Fiscal Year) | $0.46M |
| Net Income (Most Recent Fiscal Year) | $-20.64M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 26.71 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.53 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -4794.92% |
| Net Margin (Trailing 12 Months) | -4794.60% |
| Return on Equity (Trailing 12 Months) | -96.39% |
| Return on Assets (Trailing 12 Months) | -89.60% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.18 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.18 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.58 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.01 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Health Information Services |
| Common Shares Outstanding | 21.57M |
| Free Float | 18.12M |
| Market Capitalization | $8.41M |
| Average Volume (Last 20 Days) | 9.45M |
| Beta (Past 60 Months) | 2.05 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 16.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 56.72% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |